Ergoteles’s Emergent Biosolutions EBS Stock Holding History

Ergoteles’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,809	Closed	-$367K	–	1653
2022 Q2	$367K	Buy	11,809 +1,527	+15%	+$52.1K	0.01%	995
2022 Q1	$422K	Buy	+10,282	New	+$453K	0.02%	725

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Ergoteles's EBS Position: Q3 2022 in Review

Ergoteles sold out of Emergent Biosolutions (EBS) in Q3 2022, closing a stake of 11,809 shares — an estimated $367K sold.

Ergoteles first reported a position in EBS in Q1 2022 and held it in 2 quarters. The position peaked at $422K in Q1 2022. 211 funds tracked by Wall St. Rank hold EBS as of Q3 2022.

Ergoteles reported no remaining Emergent Biosolutions position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 11,809 Emergent Biosolutions shares in Q3 2022, an estimated $367K.
Ergoteles first reported a position in Emergent Biosolutions in Q1 2022 and held it in 2 quarters.
Ergoteles's Emergent Biosolutions position peaked at $422K in Q1 2022.
211 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.